Infusion of DDAVP does not improve primary hemostasis in patients with cirrhosis

Cirrhosis frequently affects multiple components of hemostasis. Reversal of the coagulopathy of these patients is frequently required in case of bleeding episodes, or as prophylaxis before invasive procedures. Although 1‐deamino‐8‐D‐arginine vasopressin (DDAVP) is widely used as a pro‐hemostatic agent in patients with cirrhosis, it is unclear whether DDAVP truly enhances hemostasis in these patients. Here we investigated the hemostatic effects of a single bolus of DDAVP in patients with cirrhosis.

[1]  R. Porte,et al.  Management of coagulation abnormalities in liver disease , 2015, Expert review of gastroenterology & hepatology.

[2]  L. Alberio,et al.  The effect of desmopressin on platelet function: a selective enhancement of procoagulant COAT platelets in patients with primary platelet function defects. , 2014, Blood.

[3]  R. Porte,et al.  Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. , 2010, Blood.

[4]  A. Burroughs,et al.  Hemostasis and thrombosis in patients with liver disease: the ups and downs. , 2010, Journal of hepatology.

[5]  T. Schiano,et al.  Intranasal desmopressin versus blood transfusion in cirrhotic patients with coagulopathy undergoing dental extraction: a randomized controlled trial. , 2010, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[6]  J. Hazelzet,et al.  Reduced ADAMTS13 in children with severe meningococcal sepsis is associated with severity and outcome , 2010, Thrombosis and Haemostasis.

[7]  P. Mannucci,et al.  An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. , 2009, Gastroenterology.

[8]  D. Takai,et al.  Increased production of ADAMTS13 in hepatic stellate cells contributes to enhanced plasma ADAMTS13 activity in rat models of cholestasis and steatohepatitis , 2009, Thrombosis and Haemostasis.

[9]  F. Nevens,et al.  Review article: blood platelet number and function in chronic liver disease and cirrhosis , 2008, Alimentary pharmacology & therapeutics.

[10]  H. Yoshiji,et al.  Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis , 2008, Thrombosis and Haemostasis.

[11]  P. Mannucci,et al.  ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis , 2007, British journal of haematology.

[12]  J. V. van Mourik,et al.  Bilirubin oxidase as a solution for the interference of hyperbilirubinemia with ADAMTS‐13 activity measurement by FRETS‐VWF73 assay , 2007, Journal of thrombosis and haemostasis : JTH.

[13]  R. Groszmann,et al.  Vascular endothelial dysfunction in cirrhosis. , 2007, Journal of hepatology.

[14]  P. D. de Groot,et al.  Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity , 2006, Hepatology.

[15]  Toshio Mori,et al.  Localization of ADAMTS13 to the stellate cells of human liver. , 2005, Blood.

[16]  J. Moake,et al.  P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface. , 2004, Blood.

[17]  R. Warters,et al.  Desmopressin before liver transplantation , 2003, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[18]  P. Knöbl,et al.  Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin. , 2003, Blood.

[19]  H. Tsai.  Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura , 2002, Journal of Molecular Medicine.

[20]  P. V. van Genderen,et al.  HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY von Willebrand Factor Propeptide in Vascular Disorders: A Tool to Distinguish Between Acute and Chronic Endothelial Cell Perturbation , 1999 .

[21]  P. Noris,et al.  In vitro and in vivo effects of desmopressin on platelet function. , 1999, Haematologica.

[22]  P. Mannucci.  Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. , 1997, Blood.

[23]  P. Mannucci,et al.  High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: Relationship to endotoxemia , 1996, Hepatology.

[24]  L. Blendis,et al.  Hepatic and portal vein thrombosis in cirrhosis: Possible role in development of parenchymal extinction and portal hypertension , 1995, Hepatology.

[25]  P. Mannucci,et al.  Randomized controlled trial of desmopressin plus terlipressin vs. terlipressin alone for the treatment of acute variceal hemorrhage in cirrhotic patients: A multicenter, double‐blind study , 1993 .

[26]  P. Mannucci,et al.  Randomized controlled trial of desmopressin plus terlipressin vs. terlipressin alone for the treatment of acute variceal hemorrhage in cirrhotic patients: a multicenter, double-blind study. New Italian Endoscopic Club. , 1993, Hepatology.

[27]  P. Mannucci,et al.  Subcutaneous Desmopressin (DDAVP) Shortens the Prolonged Bleeding Time in Patients with Liver Cirrhosis , 1990, Thrombosis and Haemostasis.

[28]  K. Rák,et al.  Desmopressin and bleeding time in patients with cirrhosis. , 1986, British medical journal.

[29]  P. Mannucci,et al.  Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time. , 1986, Blood.